Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7Z5W3
UPID:
BN3D2_HUMAN
Alternative names:
BCDIN3 domain-containing protein
Alternative UPACC:
Q7Z5W3; A8K829
Background:
RNA 5'-monophosphate methyltransferase, also known as BCDIN3 domain-containing protein, plays a crucial role in cellular processes by specifically monomethylating the 5'-monophosphate of cytoplasmic histidyl tRNA, thereby acting as a protective capping enzyme. This protein also negatively regulates miRNA processing by methylating pre-miRNAs, reducing their processing by DICER1. Its activity on pre-miR-145, although debated, highlights its potential regulatory complexity in RNA biology.
Therapeutic significance:
Understanding the role of RNA 5'-monophosphate methyltransferase could open doors to potential therapeutic strategies.